Feasibility study of target capture RNA-sequencing for B-cell acute lymphoblastic leukemia

Feasibility study of target capture RNA-sequencing for B-cell acute lymphoblastic leukemia - Feasibility study of target capture RNA-sequencing for B-cell acute lymphoblastic leukemia(NHOH-RNAseq-BALL)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038710

Enrollment

115

Registered

2019-12-16

Start date

2019-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell Acute Lymphoblastic Lekaemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Newly diagnosed, relapsed, or refractory patients who diagnosed as B-ALL (NOS) or B-ALL with recurrent genetic abnormalities by WHO classification 2016 (2) Patients whose written consent was obtained within a week from diagnosis (3) Patients who agreed to submit a specimen containing more than 10% of tumor within a week from study entry

Exclusion criteria

Exclusion criteria: Inappropriate patients judged by principal investigator or co-investigator

Design outcomes

Primary

Measure	Time frame
Frequency of subtype detection by target capture RNA-sequencing within 60 days	—

Secondary

Measure	Time frame
Frequency of subtype detection by cytogenetic testing Evaluating the time period to returning a report Consistency with the results of clinical examination (RT-PCR or FISH) Consistency with the results of other methods (RNA-seq, whole genome sequencing, target capture DNA-seq, RT-PCR) Evaluating costs of target capture RNA-seq in clinical settings Frequency of the patients who received allogeneic transplantation Frequency of the patients who received tyrosine kinase inhibitor	—

Measure

Time frame

Frequency of subtype detection by cytogenetic testing Evaluating the time period to returning a report Consistency with the results of clinical examination (RT-PCR or FISH) Consistency with the results of other methods (RNA-seq, whole genome sequencing, target capture DNA-seq, RT-PCR) Evaluating costs of target capture RNA-seq in clinical settings Frequency of the patients who received allogeneic transplantation Frequency of the patients who received tyrosine kinase inhibitor

—

Countries

Japan

Contacts

Public ContactDaiki Hirano

Nagoya Medical Center Hematology Department

hirano.daiki.jq@mail.hosp.go.jp052-951-1111

Outcome results